Focused on the discovery of new treatments under-served diseases





Pioneering new potential therapeutic for Systemic Sclerosis





Over



Our story





We are dedicated to restoring hope and quality of life to people suffering from diseases with little hope of treatment. We clinical stage pharmaceutical company with multiple compounds in development that were discovered at Emory University. We are a privately funded company and have received significant support from the Georgia Research Alliance, GRA Venture Fund, and the BioMed Investor Network.



Our vision





We are focused on the development of innovative new drugs to address under-served disease states. Our initial focus for our first-in class compounds was dermatological diseases. Thru our continuing research of the mechanism of action of our first in class compounds we have validated new highly valuable potential indications

  • Systemic Sclerosis
  • Neurological Diseases
  • MelanomaBRAF+
  • Hypertension


About Systemic Scleroderma



Systemic Scleroderma is an autoimmune disorder that affects the skin and internal organs. It is characterized by the buildup of scar tissue (fibrosis) in the skin and other organs. The fibrosis is caused by the body's production of too much collagen, which normally strengthens and supports connective tissues. The symptoms usually begin with episodes of Raynaud's phenomenon. This may be followed by puffy or swollen hands before the skin becomes thickened and hard. The fibrosis can also affect internal organs, including the esophagus, heart, lungs, and kidneys.


Unfortunately there is a high mortality associated with this disease and the key factors are:

-Pulmonary fibrosis

-Cardiac fibrosis


Systemic Scleroderma is considered and orphan disease with a prevalence of:

-100,000-US

-180,000-EU -


Currently there are no approved treatments f0r Systemic Scleroderma and new therapeutic alternatives are desperately needed.



​ABOUT HIV Associated
Neurocognitive Disorder (HAND)



Neurocognitive Disorder (HAND) Neurocognitive

impairment (NCI) associated with HIV infection of brain

impacts a large proportion of people with HIV regardless of antiretroviral therapeutics

-1.2 Million in the US are HIV positive/30K new cases/year

-44%+ or 500K will develop Neurocognitive Disorders

-10.6% or 127K have moderate/severe cognitive

impairment.


Common Symptoms Decline in thinking, or "cognitive,"

functions such as memory, reasoning, judgment,

concentration, problem solving, personality, behavior,

speech, and motor (movement)


Currently there are no approved treatments f0r HAND and

new therapeutic alternatives are desperately needed.



​ABOUT Melanoma BRAF+



The American Cancer Society’s estimates for melanoma in the United States for 2022 are:


-99,780 new melanomas will be diagnosed The rates of melanoma have been rising rapidly over the past few decades,

-7,650 people are expected to die of melanoma in the US annually


The most prevalent melanoma mutation is BRAF(V600E), which constitutively activates downstream MAPK signaling.


Vemurafenib has remarkable clinical activity in BRAF(V600E)-positive melanoma tumors.


Patients often rapidly develop resistance to vemurafenib treatment and new treatments are desperately needed.



Our Partners



307 Mary St
Clarkesville, GA 30523


CALL: 678-812-1492



Accuitis, Inc.